toxicité (1) sécurité (1) maladie (1) coût (1) ligne (1) cancer (1) survie (1) Treatment (1) Chemotherapy (1) Cancer (1) Inhibitors (1) Trastuzumab (1) Paclitaxel (1) Rates (1) Values (1) Tumors (1) Trials (1) Survival (1) Strategy (1) Poor (1) Patients (1) Meta-analysis (1) Human beings (1) Immunotherapy (1) Cost (1) Chemotherapy (1) Cancer (1) Breast (1) Algorithms (1) Bevacizumab (1)